A5010083131- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Cardiovascular Function and Risk Factors
- Adipose Tissue and Metabolism
- Diabetes Management and Research
- Diet and metabolism studies
- Hormonal Regulation and Hypertension
- Pharmacology and Obesity Treatment
- Liver Disease Diagnosis and Treatment
- Diabetes and associated disorders
- Cardiovascular Disease and Adiposity
- Ion Transport and Channel Regulation
- Systemic Sclerosis and Related Diseases
- Heart Failure Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac Imaging and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Muscle metabolism and nutrition
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Parathyroid Disorders and Treatments
- Advanced MRI Techniques and Applications
- Dialysis and Renal Disease Management
- Vitamin D Research Studies
- Diabetes Management and Education
The University of Texas Health Science Center at San Antonio
2015-2024
The University of Texas Health Science Center at Houston
2020-2024
The University of Texas at San Antonio
2017-2024
Texas Diabetes Institute
2013-2023
University Health System
2020-2023
Ospedale Sant Antonio
2020
Urology San Antonio
2019
Audie L. Murphy Memorial VA Hospital
2015
The University of Texas of the Permian Basin
2014
Texas Tech University
2014
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue disposal patients type diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo 6) for weeks. We measured whole body uptake and endogenous...
Insulin resistance is associated with mitochondrial dysfunction and decreased ATP synthesis. Treatment of individuals type 2 diabetes mellitus (T2DM) sodium-glucose transporter inhibitors (SGLT2i) improves insulin sensitivity. However, recent reports have demonstrated development ketoacidosis in subjects T2DM treated SGLT2i. The current study examined the effect improved sensitivity dapagliflozin on 1) synthesis 2) substrate oxidation rates ketone production.The randomized 18 to (n = 9) or...
Abstract Background: β-Cell dysfunction is a core defect in T2DM, and chronic, sustained hyperglycemia has been implicated progressive β-cell failure, ie, glucotoxicity. The aim of the present study was to examine effect lowering plasma glucose concentration with dapagliflozin, glucosuric agent, on function T2DM individuals. Research Design Methods: Twenty-four subjects received dapagliflozin (n = 16) or placebo 8) for 2 weeks, 75-g oral tolerance test (OGTT) insulin clamp were performed...
Abstract Objective To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients type 2 diabetes mellitus (T2DM). Methods Patients T2DM (N = 15) received (25 mg/d) for weeks. β-Cell was measured a nine-step hyperglycemic clamp (each step, 40 mg/dL) before and at 48 hours 14 days after initiating empagliflozin. Results Glucosuria recorded on 1 [mean ± standard error of mean (SEM), 101 10 g 117 11 g,...
To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S).We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments placebo (P), M, S, M+S. After each period, subjects received a 6-h meal tolerance test (MTT) [(14)C]glucose calculate glucose kinetics. Fasting plasma (FPG), fasting insulin, C-peptide (insulin secretory rate [ISR]), glucagon, bioactive glucagon-like peptide (GLP-1) gastrointestinal insulinotropic (GIP)...
OBJECTIVE To examine the effect of pioglitazone on myocardial insulin sensitivity and left ventricular (LV) function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Twelve subjects T2D 12 normal glucose tolerance received a euglycemic clamp. Myocardial uptake (MGU) perfusion were measured [18F]fluoro-2-deoxy-d-glucose [15O]H2O positron emission tomography before after 24 weeks treatment. transmitral early diastolic relation/atrial contraction (E/A) flow ratio magnetic...
Finerenone, a selective nonsteroidal MRA, and SGLT2is both reduce CKD progression improve kidney/CV outcomes. The CONFIDENCE study (NCT05254002; EudraCT 2021-003037-11) hypothesis is that early combination of finerenone empagliflozin, SGLT2i, superior to either drug alone in reducing UACR over 6 months. an ongoing, fully enrolled, randomized, controlled, double-blind, multicentre phase 2 clinical trial adults (≥18 years age) with T2D, eGFR 30 90 ml/min/1.73 m2, ≥100 <5000 mg/g. Participants...
To investigate the effect of lowering plasma glucose and free fatty acid (FFA) concentrations with dapagliflozin acipimox, respectively, on insulin sensitivity secretion in T2DM individuals. Fourteen male patients received an oral tolerance test euglycemic hyperinsulinemic clamp at baseline were treated for 3 weeks (10 mg per day). During week 3, acipimox (250 four times day) treatment was added to dapagliflozin. The repeated end 2 3. Dapagliflozin caused glucosuria significantly lowered...
To examine the effect of pioglitazone on epicardial (EAT) and paracardial adipose tissue (PAT) measures diastolic function insulin sensitivity in patients with type 2 diabetes mellitus (T2DM).
Abstract Aims/hypothesis The glucosuria induced by sodium–glucose cotransporter 2 (SGLT2) inhibition stimulates endogenous (hepatic) glucose production (EGP), blunting the decline in HbA 1c . We hypothesised that, response to glucosuria, a renal signal is generated and EGP. To examine effect of acute administration SGLT2 inhibitors on EGP, we studied non-diabetic individuals who had undergone transplant with without removal native kidneys. Methods This was parallel, randomised, double-blind,...
The aim of the current study was to evaluate effect sustained physiologic increase ∼50 mg/dL in plasma glucose concentration on insulin secretion normal glucose-tolerant (NGT) subjects. Twelve NGT subjects without family history type 2 diabetes mellitus (T2DM; FH−) and 8 with T2DM (FH+) received an oral tolerance test two-step hyperglycemic clamp (100 300 mg/dL) followed by intravenous arginine bolus before after 72-h infusion. Fasting increased from 94 ± 142 4 for 72 h. First-phase (0–10...
Partial leptin reduction can induce significant weight loss, while loss contributes to partial reduction. The cause-and-effect relationship between and remains be further elucidated. Here, we show that FGF21 the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a in leptin. This contributed beneficial effects of GLP-1R agonism metabolic health, as transgenically maintaining levels during treatment partially curtailed seen with these agonists. Moreover, higher...
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibition causes an increase in endogenous glucose production (EGP). However, the mechanisms are unclear. We studied effect of SGLT2 inhibitors on EGP subjects with type diabetes (T2D) and without (non-DM) kidney transplant recipients renal denervation. RESEARCH DESIGN AND METHODS Fourteen who received a (six T2D [A1C 7.2 ± 0.1%] eight non-DM 5.6 0.1%) underwent measurement [3-3H]glucose infusion following dapagliflozin (DAPA) 10 mg or...
Abstract Purpose To provide pharmacists with information on counseling patients type 2 diabetes (T2D) receiving oral semaglutide. Summary Oral semaglutide, the first glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA), was approved for treatment of adults T2D by US Food and Drug Administration in September 2019. Semaglutide has been coformulated absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate to improve bioavailability semaglutide following administration. shown...
Mitochondrial function has been examined in insulin-resistant (IR) states including type 2 diabetes mellitus (T2DM). Previous studies using phosphorus-31 magnetic resonance spectroscopy ( 31 P-MRS) T2DM reported results as relative concentrations of metabolite ratios, which could obscure differences phosphocreatine ([PCr]) and adenosine triphosphate ([ATP]) between normal glucose tolerance (NGT) individuals. We used an image-guided P-MRS method to quantitate [PCr], inorganic phosphate [Pi],...
Oral administration of peptide therapeutics faces challenges because the distinct environment gastrointestinal tract. An oral formulation semaglutide, a glucagon-like 1 receptor agonist, was approved by U.S. Food and Drug Administration in 2019 as therapy for treatment type 2 diabetes. semaglutide uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) technology to enhance absorption stomach protect it from degradation gastric enzymes. This article presents summary studies investigating...
We examined the effect of increased plasma ketones on left ventricular (LV) function, myocardial glucose uptake (MGU), and blood flow (MBF) in type 2 diabetes (T2DM) patients with heart failure (HF). Three groups (I,II,III) T2DM (12 per group) LV ejection fraction ≤50% received incremental infusions β-OH-B for 3-6 hours to raise concentration throughout physiologic (Groups I II) pharmacologic (Group III) range. Cardiac MRI was performed at baseline after each infusion provide measures...